A buyout consortium comprising Warburg Pincus and Advent International is in advanced talks to acquire Baxter International Inc’s (NYSE: BAX) biopharma solutions business.
BioPharma Solutions offers contract manufacturing services to the pharma and biotech industries. The deal value could reach or exceed $4 billion.
Warburg Pincus and Advent have submitted the most attractive offer to Baxter in an auction that drew interest from other private equity firms and major players, including Thermo Fisher Scientific Inc (NYSE:
